These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23173130)

  • 1. Glargine and cancer: can we now suggest closure?
    Owens DR
    Diabetes Care; 2012 Dec; 35(12):2426-8. PubMed ID: 23173130
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin degludec: a new insulin for today?
    Hitman GA
    Diabet Med; 2013 Nov; 30(11):1267. PubMed ID: 24134602
    [No Abstract]   [Full Text] [Related]  

  • 3. Insulin degludec (Tresiba)--a new long-acting insulin for diabetes.
    Med Lett Drugs Ther; 2015 Dec; 57(1483):163-4. PubMed ID: 26633683
    [No Abstract]   [Full Text] [Related]  

  • 4. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
    Becker RH; Nowotny I; Teichert L; Bergmann K; Kapitza C
    Diabetes Obes Metab; 2015 Mar; 17(3):261-7. PubMed ID: 25425394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.
    Bolli GB; Hahn AD; Schmidt R; Eisenblaetter T; Dahmen R; Heise T; Becker RH
    Diabetes Care; 2012 Dec; 35(12):2626-30. PubMed ID: 23093664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes.
    Lucidi P; Porcellati F; Rossetti P; Candeloro P; Andreoli AM; Cioli P; Hahn A; Schmidt R; Bolli GB; Fanelli CG
    Diabetes Care; 2012 Dec; 35(12):2647-9. PubMed ID: 23086139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U300, a novel long-acting insulin formulation.
    Sutton G; Minguet J; Ferrero C; Bramlage P
    Expert Opin Biol Ther; 2014 Dec; 14(12):1849-60. PubMed ID: 25311556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile?
    Hood RC
    Diabetes Technol Ther; 2017 Apr; 19(4):203-205. PubMed ID: 28418731
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
    Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Brief: Semglee - a new insulin glargine for diabetes.
    Med Lett Drugs Ther; 2021 Jan; 63(1616):14-15. PubMed ID: 33512347
    [No Abstract]   [Full Text] [Related]  

  • 13. Not all long-acting insulins are the same.
    Harmel AL; Somma L
    Diabetes Care; 2002 Sep; 25(9):1666-7. PubMed ID: 12196454
    [No Abstract]   [Full Text] [Related]  

  • 14. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early insulin treatment in type 2 diabetes--no].
    Nauck M
    Dtsch Med Wochenschr; 2013 May; 138(18):957. PubMed ID: 23613376
    [No Abstract]   [Full Text] [Related]  

  • 16. Insulin is not insulin and a unit not a unit.
    Vaag A
    Diabetes Obes Metab; 2015 Mar; 17(3):217-8. PubMed ID: 25352063
    [No Abstract]   [Full Text] [Related]  

  • 17. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus.
    Pfützner A; Hermanns N; Funke K; Forst T; Behnke T; Bitton G; Nagar R; Raz I; Haak T
    Curr Med Res Opin; 2014 May; 30(5):753-60. PubMed ID: 24392996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to Hitman. Insulin degludec: a new insulin for today?
    Schmidt TA
    Diabet Med; 2014 Mar; 31(3):377-8. PubMed ID: 24354502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.